Inocencio Cuesta, MD
Rheumatology · Ann Arbor, MINPI 1992746820
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,525 of the $12,316 with a category attached, or 69.2%. AbbVie accounts for 61.3% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $9,267 and has fallen 88.1% since, to $1,101 in 2024.
Across 181 payments — averaging $68.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Amgen$3K
- Johnson & Johnson$483
- AstraZeneca$162
- UCB, Inc.$156
- Pfizer$154
- plus $893 from 18 others
What the payments were for
- Speaking & faculty fees$8,52569%
- Travel & lodging$2202%
- Food & beverage$3,20826%
- Education$3633%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $7,549 |
| Amgen(2 entities) | 37 | $2,918 |
| Johnson & Johnson | 26 | $483 |
| AstraZeneca(2 entities) | 6 | $162 |
| UCB, Inc. | 6 | $156 |
| Pfizer | 6 | $154 |
| Aurinia Pharma U.S., Inc. | 7 | $133 |
| Boehringer Ingelheim | 6 | $127 |
| GSK | 4 | $71 |
| Radius Health, Inc. | 4 | $70 |
| Novartis | 2 | $54 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $51 |
| Organon | 2 | $47 |
| Mylan Institutional Inc. | 2 | $46 |
| Averitas Pharma Inc. | 2 | $45 |
| Genentech USA, Inc. | 2 | $45 |
| Fresenius Kabi USA, LLC | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Sanofi | 1 | $32 |
| Sandoz | 1 | $27 |
| BETA Bionics, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Celltrion USA Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,316 in reported general payments places this provider in the 75th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 71 | $531,087 |
| Humira(Cf) PenAdalimumab | 73 | $495,516 |
| Humira PenAdalimumab | 44 | $292,921 |
| EnbrelEtanercept | 21 | $176,614 |
| Yuflyma(Cf) Autoinject (2 Pck)Adalimumab-Aaty | 18 | $127,959 |
| InflectraInfliximab-Dyyb | 13 | $112,932 |
| XeljanzTofacitinib Citrate | 11 | $62,579 |
| MethotrexateMethotrexate Sodium | 754 | $19,026 |
| Hydroxychloroquine Sulfate | 484 | $18,038 |
| SavellaMilnacipran Hcl | 12 | $6,178 |
| Leflunomide | 77 | $4,111 |
| Sulfasalazine | 155 | $3,749 |
| Prednisone | 316 | $2,620 |
| Azathioprine | 57 | $2,523 |
| Leucovorin Calcium | 40 | $2,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $2,918 | $176,61421 claims |
| PfizerInflectra, Xeljanz | $154 | $175,51124 claims |
| AbbVieSavella | $7,549 | $6,17812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 195 rheumatology providers in Michigan.
Other rheumatology in Ann Arbor
- Dinesh KhannaAnn Arbor$1.2M
- Elena SchiopuAnn Arbor$180K
- Daniel ClauwAnn Arbor$102K
- Katherine ChakrabartiAnn Arbor$82K
- Puja KhannaAnn Arbor$78K
- Joanne KahlenbergAnn Arbor$74K
- John VargaAnn Arbor$64K
- Samardeep GuptaAnn Arbor$58K
- Jason KnightAnn Arbor$38K
- Sheeja FrancisAnn Arbor$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.